姣忔湀鑽墿蹇-2014骞?鏈圏/h1>
鏃堕棿锛?014-2-28 11:41:23
FDA 鎵瑰噯 ISENTRESS 鍎跨鐢ㄥ彛鏈嶆贩鎮恫
Merck & Co. 鍏徃鎵€浜 Isentress(R)锛堟媺鏇挎媺闊﹂捑锛宺altegravir potassium锛夊彛鏈嶆贩鎮恫鏄暣鍚堥叾鎶戝埗鍓傚埗鎴愮殑涓€绉嶅効绔ユ柊鑽紝宸茶幏 FDA 鎵瑰噯銆侷sentress 鍙f湇娣锋偓娑查€傜敤浜庝綋閲嶄粙浜 3 鈥 20 kg 鐨 4 鍛ㄩ緞浠ヤ笂鎮h€咃紝涓庡叾浠栨姉閫嗚浆褰曠梾姣掕嵂鑱旂敤娌荤枟 HIV-1 鎰熸煋銆傝繖绉嶅彛鏈嶆贩鎮恫鍒跺墏棰勮灏嗗湪 2014 骞寸涓夊搴﹀紑鍞€傝鍏徃鍐嶆帴鍐嶅帀锛屽姏浜夊湪鍏朵粬鍥藉鐢虫姤杩欎竴鍙f湇娣锋偓娑层€侷sentress 杩樻嫢鏈夊拃鍤肩墖鍜岃杽鑶滆。鐗囧墏鍨嬶紝宸插湪 35 涓浗瀹惰幏鎵圭敤浜 2 宀佷互涓 HIV-1 鍎跨鍜岄潚灏戝勾鐨勮仈鍚堟不鐤椼€侷sentress 鐢ㄤ綔 HIV-1 棣栨不鎴愪汉鎮h€呰仈鍚堟不鐤楃殑鎴愬垎鑽凡鍦 76 涓互涓婂浗瀹惰幏鎵癸紝鐢ㄤ簬 HIV 澶嶆不鎴愪汉鎮h€呭凡鍦 114 涓互涓婂浗瀹惰幏鎵癸紙Merck & Co. 鏂伴椈绋匡級銆
纭涓€绉嶉闃茶浆绉荤殑灏忓垎瀛愯禆姘ㄩ叞-TRNA 鍚堟垚閰舵姂鍒跺墏
涓€瀹跺浗闄呮€ф満鏋勫€熷姪榧犵檶鐥囨椿浣撳唴妯″瀷锛屼粙缁嶄簡灏忓垎瀛 BC-K-YH16899 (Yuhan) 濡備綍鎶戝埗璧栨皑閰?tRNA 鍚堟垚閰朵笌 67-kDa 灞傜矘杩炶泲鐧藉彈浣撶殑鐩镐簰浣滅敤銆傝禆姘ㄩ叞-tRNA 鍚堟垚閰 (KARS) 鍙娇 67-kDa 灞傜矘杩炶泲鐧藉彈浣 (67LR) 绋冲畾锛岃€屽悗鑰呭垯鍙備笌浜嗙檶鐥囪浆绉汇€傚湪浜轰綋鑲洪碁鐘剁粏鑳炵檶 NCI-H226 缁嗚優涓紝KARS 杩囪〃杈惧寮轰簡 67LR 鐨勭ǔ瀹氭€э紝淇冭繘浜嗙粏鑳炶縼绉诲拰渚佃锛岀▼搴︽槸鍘熸潵鐨 3 鍊嶃€傚皢绋冲畾杩囪〃杈 KARS 鐨勯珮杞Щ鎬ч紶 4T1 涔宠吅鐧岀粏鑳炴敞鍏ュ皬榧犱綋鍐咃紝鑲虹粨鑺傝鏁板鍔犱竴鍊嶃€傚鐐欐墜鍙儹鐨勫寲鍚堢墿 BC-K01 杩涜閰垫瘝鍙屾潅浜ょ瓫閫夊拰缁撴瀯鎬ф敼鑹紝閴村畾鍑轰簡灏忓垎瀛 BC-K-YH16899锛屾鐗╂渶楂樺彲棰勯槻 80% KARS-67LR 鐩镐簰浣滅敤銆佺粏鑳炲舰鐘舵敼鍙樺強缁嗚優渚佃銆傛敞灏勪簡 4T1 缁嗚優鐨勫皬榧犱腑锛孊C-K-YH16899锛?00 鍜 300 mg/kg p.o.锛変娇鑲鸿浆绉绘姂鍒朵簡 60%.Tg(MMTV-PyVT) 灏忛紶浣撳唴 KARS 鍜 67LR杩囧害琛ㄨ揪锛屽彂鐢熶簡鍘熷彂涔宠吅鐧屼即鑲鸿浆绉汇€傜粰浜 BC-K-YH16899 (100 mg/kg p.o.) 鍚庯紝杩欎簺灏忛紶鐨勮偤缁撹妭璁℃暟鍑忓皯浜 70%銆傜粰姝e父灏忛紶宸﹀績瀹ゆ敞鍏ヤ汉浣撹偤鐧 A549 缁嗚優锛屼骇鐢熶簡澶ц剳鍜岄鑲跨槫銆傚湪姝ゆā鍨嬩腑锛孊C-K-YH16899 娌荤枟浣胯偪鐦ょ殑鍙戠敓鏄捐憲鍑忓皯浜 50% 宸﹀彸銆備换浣曟椿浣撳唴妯″瀷涓紝璇ヨ嵂閮芥湭褰卞搷浣撻噸锛屾湭瑙佸壇浣滅敤銆傚 BC-K-YH16899 浣滅敤鏈哄埗鐨勮皟鏌ユ樉绀猴紝璇ヨ嵂鍦ㄦ畫鍩 1-207 澶勪笌 KARS 鐨 N-绔粨鍚堬紝浠庤€屾姂鍒朵簡杩欎竴浣嶇偣 KARS 涓 67LR 鐨勭浉浜掍綔鐢ㄣ€傛澶栵紝BC-K-YH16899 闃绘浜 KARS 浠庤優璐ㄦ憾鑳舵槗浣嶅埌缁嗚優鑶滐紙Kim, D.G. et al. Nat Chem Biol 2014, 10(1): 29锛夈€備笓鍒╂枃鐚腑浠嬬粛浜嗚鍖栧悎鐗 (WO 2013043001)銆
娌荤枟鐧岀棁鐨勫彉鏋勫皬鍒嗗瓙纾烽吀閰舵姂鍒跺墏闂笘
GlaxoSmithKline 鍏徃鎶ラ亾鍒舵垚浜嗕竴绉嶅彛鏈嶆湁鏁堢殑閲庣敓鍨 p53-璇卞铔嬬櫧纾烽吀閰 1 (PP2C-delta)寮傛瀯鎶戝埗鍓 GSK-2830371, 缁忎复搴婂墠鐮旂┒纭畾浜嗗叾鐗圭偣锛屽湪娲讳綋澶栨垨娲讳綋鍐呴兘鍙姂鍒惰偪鐦ょ粏鑳炵敓闀裤€傝繖绉嶈泲鐧界7閰搁叾鐢 PPM1D 鍩哄洜缂栫爜锛屽緢澶氱檶鐥囦腑閮芥湁鎵╁锛屽叾杩囪〃杈句笌鑲跨槫褰㈡垚鏈夊叧銆傜爺绌朵汉鍛樺紑鍙戜簡涓€绯诲垪绉颁箣涓?甯界姸姘ㄥ熀閰?鐨勫皬鍒嗗瓙铔嬬櫧纾烽吀閰跺紓鏋勬姂鍒跺墏锛屽叾缁勬垚鍖呮嫭姘ㄥ熀閰告牱鏍稿績鍙婁晶闈㈢殑鍙慨楗板熀鍥€傝繖浜涘熀鍥笌铔嬬櫧纾烽吀閰剁嫭鐗圭殑鐡g姸缁撴瀯鍩熷叿鏈夐珮浜插悎鍔涖€侴SK-2830371 鐗瑰紓鎬у己鏁堟姂鍒朵簡纾?p38 涓濊鍘熸椿鍖栬泲鐧芥縺閰剁殑 PP2C-未 鑴辩7閰革紝IC50 涓 13 nM銆傝〃鐜版湁 PPM1D-鎵╁缁嗚優绯荤殑涔宠吅鐧屻€佹穻宸寸槫鍜屾€ユ€ф穻宸存瘝缁嗚優鐧借鐥呬腑锛孏SK-2830371 浠ユ祿搴︿緷璧栨柟寮忓彲閫嗘€у鍔犱簡铔嬬櫧纾烽吀閰跺簳鐗╃殑纾烽吀鍖栥€傚湪 PPM1D-鎵╁ TP53 閲庣敓鍨嬩汉涔宠吅鐧 MX-1 鎴 MCF7 缁嗚優涓紝GSK-2830371 寮曞彂浜嗘祿搴︿緷璧栨€х敓闀挎姂鍒躲€備笌姝ょ浉鍙嶏紝鍦 PPM1D-鎵╁ p53-绐佸彉涔宠吅瀵肩鐧 BT-474 缁嗚優涓紝GSK-2830371 鍗村鍏嬮殕褰㈡垚鏃犱綔鐢ㄣ€傛澶栵紝GSK-2830371 鎶戝埗浜嗛殣钘忔湁閲庣敓鍨 TP53 娣嬪反鏍风粏鑳炵郴鐨勫娈栵紝鎻愮ず铔嬬櫧纾烽吀閰舵姂鍒剁殑鎶楃敓闀夸綔鐢ㄦ槸鐢 p53 娲诲寲鎵€浠嬪鐨勩€傚紓绉嶇Щ妞 PPMID-鍓湰鐨勫皬榧犻潪闇嶅閲 B 缁嗚優 (DoHH2) 涓紝鍙f湇 GSK-2830371 浣 p53 鐨勭7閰稿寲寤堕暱浜 6 灏忔椂锛屼笌鍏跺湪灏忛紶浣撳唴鍗婅“鏈熻緝鐭竴鑷淬€傛瘡鏃ヤ娇鐢ㄤ袱娆℃垨涓夋 GSK-2830371 (150 mg/kg)锛屽垎鍒娇鑲跨槫鐢熼暱鎶戝埗浜 41% 鍜 68%銆傝泲鐧界7閰搁叾鎶戝埗瀵艰嚧纾烽吀搴曠墿 p53 鍜 Chk2 鏄庢樉澧炲姞鍙婅泲鐧界7閰搁叾娴撳害闄嶄綆锛圙ilmartin, A.G. et al. Nat Chem Biol 2014, Advanced publication锛夈€ 涓撳埄鏂囩尞涓粙缁嶄簡璇ュ寲鍚堢墿 (WO 2012149102)銆
KARYOPHARM 鍏徃浠 PAK-4 娌荤枟鑳拌吅鐧屼綔涓虹洰鏍
Karyopharm 鍏徃鐮旂┒浜哄憳寮€鍙戜簡涓濇皑閰?鑻忔皑閰歌泲鐧芥縺閰 PAK 4 (PAK-4) 鐨勫彉鏋勮皟鑺傚墏锛屼复搴婂墠璇曢獙涓娌荤枟鑳拌吅鐧岃〃鐜板嚭甯屾湜銆傝繖浜涘寲鍚堢墿鍦ㄨ儼鑵虹檶缁嗚優涓〃鐜板嚭鎶楀娈栨椿鎬э紙IC50 < 250 nM锛夛紝鍗翠笉浼氬奖鍝嶆甯镐汉浣撹儼绠′笂鐨粏鑳炪€傚湪娲讳綋澶栫爺绌朵腑锛孠PT-7189 涓 PAK-4 铔嬬櫧琛ㄨ揪闄嶄綆鍙婃姉鍑嬩骸淇″彿浼犻€掗€嗚浆鏈夊叧锛孭AK4 RNA 骞叉壈鍒欏寮轰簡 KPT-7189 鐨勬椿鎬с€侹PT-7189 鎶戝埗浜嗘惡甯︾檶鐥囧共缁嗚優鏍囪鐗╁苟楂樺害鑰愯嵂鑳拌吅鐧岀粏鑳炲舰鎴愮悆鐘朵綋鐨勮兘鍔涳紝涓庝竴绉嶄笂鐨埌闂磋川琛ㄥ瀷鐩哥銆傚彟涓€绉 PAK-4 鍙樻瀯璋冭妭鍓 KPT-7651 鍦ㄥ皬榧犱腑琛ㄧ幇鍑 95% 鐨勫彛鏈嶇敓鐗╁埄鐢ㄥ害锛屽苟鍙壇濂借€愬彈锛屾渶楂樿€愬彈鍙f湇鍓傞噺鏄 60 mg/kg銆傜洰鍓嶆鍦ㄥ鐨笅銆佸父浣嶅拰 LSL-KrasG12D/+銆丩SL-Trp53R172H/+銆丳dx-1-Cre 杞熀鍥犲皬榧犲紑灞曡繘涓€姝ヨ皟鏌 (Azmi, A.S. et al. Gastrointest Cancers Symp (Jan 16-18, San Francisco) 2014, Abst 233)銆侴astrointest Cancers Symp (Jan 16-18, San Francisco) 2014, Abst 233).
GLAXOSMITHKLINE 鎶ラ亾娌荤枟澶氬彂鎬ч楂撶槫鐨勬柊鍨嬫姉浣 鈥 鑽墿缁撳悎鐗
GSK-2857916锛圝6M0-mcMMAF锛汫laxoSmithKline锛夋槸涓€绉嶆柊鍨嬩汉鍖 Fc-鏀归€犳姉 B-缁嗚優鎴愮啛鎶楀師 鈥 鍗曠敳鍩哄ゥ閲屾柉浠栨眬 (auristatin) F 鍗曞厠闅嗘姉浣 (MAb)鈥 鑽墿缁撳悎鐗╋紝鎷熺敤浜庢不鐤楀鍙戞€ч楂撶槫 (MM)锛屽凡瀹炴柦浜嗕复搴婂墠鐮旂┒璇勪环鍏舵椿鎬с€侴SK-2857916 瀵 TNF 閰嶄綋瓒呭鏃忔垚鍛?3B (BAFF) 鍜 13 (APRIL) 鐨 IC50 鍒嗗埆涓 0.91 鍜 2.43 mcg/mL銆備笌 J6M0-vcMMAE 鐩告瘮锛屽彂鐜 GSK-2857916 鏁堟灉鏇村己锛孖C50 鍊煎垎鍒负 11.5 鍜 55.8 ng/mL銆侴SK-2857916 闃绘柇浜 MM 缁嗚優鐨勭敓闀垮拰瀛樻椿銆備笌楠ㄩ珦鍩鸿川缁嗚優涓€璧峰煿鍏伙紝GSK-2857916锛?銆?.001銆?.01銆?.1銆?.0 鍜 10 mcg/mL锛夐€夋嫨鎬ф姂鍒朵簡缁嗚優娲诲姏銆備笌 J6M0-姝e父 Fc 鐩告瘮鏃讹紝J6M0-mcMMAF 瀵规姉浣撲緷璧栫粏鑳炰粙瀵肩粏鑳炴瘨鎬х殑璇卞浣滅敤鏇村己銆備娇鐢 J6M0-mcMMAF锛屾偅鑰呰嚜浣 MM 缁嗚優婧惰В鏄庢樉澧炲銆傚甫鏈 H929 鍜 OPM2 缁嗚優绯诲紓绉嶇Щ妞嶆ā鍨嬩腑锛孞6M0-mcMMAF锛? 鍜 4 mg/kg锛変笌瑁 J6M0 (2 mg/kg) 鐩告瘮琛ㄧ幇鍑烘洿涓哄己澶х殑鎶 MM 娲绘€с€傚讥婕€ SCID-beige MM 妯″瀷涓紝瑙傚療鍒 J6M0-mcMMAF锛?.4 鍜 4 mg/kg锛変笌 J6M0 (4 mg/kg) 鍜岃祴褰㈠墏鐩告瘮锛屼娇 MM 鑲跨槫蹇€熸秷闄ゅ苟寤堕暱浜嗙敓瀛樻湡銆侸6M0-mcMMAF 娌荤枟鍚庤瀵熷埌 MM 缁嗚優涓鍙戜簡鍚炲櫖浣滅敤锛圱ai, Y.-.T. et al. Annu Meet Am Soc Hematol (Dec 7-10, New Orleans) 2013, Abst 877锛夈€ 涓撳埄鏂囩尞涓粙缁嶄簡杩欑鎶椾綋 鈥 鑽墿缁撳悎鐗 (WO 2012163805)銆
涓€绉嶆姉鐐庡拰淇冨噵浜″弻閲嶅姛鑳借嵂鐗╃殑鏈烘鐗规€
涓編涓ゅ浗鐨勭爺绌朵汉鍛樹粙缁嶄簡鎶楃値銆佷績鍑嬩骸鐨勭幆鍔犳哀閰?2/5-鑴傛哀鍚堥叾 (COX-2/5-LOX) 鍙岄噸鎶戝埗鍓 KYKZL-1 鐨勪綔鐢ㄦ満鍒躲€侰OX 鍜 LOX 鍦ㄤ汉浣撶檶鐥囦腑涓婅皟锛屼綔鐢ㄦ湁淇冭繘缁嗚優杩佺Щ銆佷镜琚€佽绠″彂鐢?缁嗚優鍛ㄦ湡鍙戝睍鍙婃姂鍒跺噵浜★紝涓虹値鐥囧拰鐧岀棁涔嬮棿寤虹珛浜嗚仈绯汇€侹YKZL-1 鏄竴绉嶆柊鍨嬫姉鐧岃嵂锛屽彲鍑忚交鐐庣棁鍙嶅簲鍜岃鍙戠粏鑳炲噵浜★紝鏈枃涓村簥鍓嶇爺绌朵腑璇佹槑浜嗚繖鐐广€ COX 鍜 LOX 鍒嗗埆浠嬪鐐庣棁浠嬭川鍓嶅垪鑵虹礌鍜岀櫧涓夌儻鐨勪骇鐢熴€侹YKZL-1 鏄竴绉嶅弻閲 COX-2/5-LOX 鎶戝埗鍓傦紝琛ㄧ幇鍑哄己澶х殑鎶楀娈栨椿鎬с€侹YKZL-1 鏄捐憲闄嶄綆浜嗕汉鑲濈粏鑳炵檶 Hep G2 缁嗚優涓 COX-2 鍜 5-LOX 鐨勮〃杈俱€傜粏鑳炵敤 KYKZL-1 澶勭悊 48 灏忔椂锛屼娇鏃╂湡鍜屽悗鏈熷噵浜$粏鑳炶緝瀵圭収鍓傚鐞嗗澶 1 鍒 5 鍊嶃€傜粏鑳炵毐缂┿€佺粏鑳炴牳鍥虹缉鍜岀瑁傛槑鏄撅紝璇存槑鍑嬩骸澧炲姞銆傛澶栵紝KYKZL-1-澶勭悊缁嗚優 Hep G2 鍋滄粸鍦ㄧ粏鑳炲懆鏈熺殑 S 鏈熴€侹YKZL-1 鎶戝埗浜嗗墠鍒楄吅绱 E2 (PGE2) 鐧戒笁鐑 B4 (LTB4) 鐨勪骇鐢燂紝鍔犲叆澶栨簮鎬 PGE2 鎴 LTB4 閫嗚浆浜嗚鑽殑鐢熼暱鎶戝埗浣滅敤銆傝鑽繕鏀瑰彉浜嗕笣瑁傚師娲诲寲铔嬬櫧婵€閰堕€氳矾鍚勯儴浠剁殑纾烽吀鍖栫姸鎬侊紝鎻愮ず杩欎竴閫氳矾鏄 COX/LOX 鐨勪笅娓哥洰鏍囥€侹YKZL-1 杩橀€氳繃閲婃斁 COX/LOX 闈炰緷璧栨€х嚎绮掍綋缁嗚優鑹茬礌 C锛岃鍙戜簡鍑嬩骸锛屽崌楂樹簡鑳卞ぉ铔嬬櫧閰 (caspase)-3 姘村钩锛屼笅璋冧簡 Bcl-2/BAX 姣斿€笺€侹YKZL-1 鐨勬墍鏈夊弽搴旈兘鍛堟祿搴︿緷璧栨€с€傝嫢寤堕暱娌荤枟闃舵鎴栦笌椤洪搨涓€璧疯仈鐢ㄨ鑽紝鍒欐姂鍒剁粏鑳炵敓闀挎墍闇€鐨勮嵂鐗╂祿搴﹁緝浣庯紙Cheng, J. et al. Toxicol Appl Pharmacol 2014, 274(1): 96锛夈€ 浜岀敳鑻瀵兼€ユ€ц€虫按鑲块紶妯″瀷涓紝鍙f湇 KYKZL-1 棰勫厛澶勭悊浠ュ墏閲忎緷璧栨柟寮忓噺杞讳簡姘磋偪锛屼笌璧嬪舰鍓傛不鐤楄€崇浉姣旀渶楂樻姂鍒剁▼搴︿负 70%锛岄珮浜庝娇鐢ㄥ弻姘姮閰告墍瑙佺殑鎶戝埗绋嬪害 (50%)銆俆PA 璇卞鎬ユ€ц€虫按鑲块紶妯″瀷涓紝KYKZL-1 浠ュ墏閲忎緷璧栨柟寮忓噺杞讳簡姘磋偪锛屼笌璧嬪舰鍓傛不鐤楄€崇浉姣旀渶楂樻姂鍒剁▼搴︿负 64%锛岄珮浜庝娇鐢ㄥ弻姘姮閰告墍瑙佺殑鎶戝埗绋嬪害 (52%)銆備笌鍙屾隘鑺吀鐩告瘮锛孠YKZL-1 瀵硅儍绮樿啘鐨勫壇浣滅敤杈冨皯锛岀矘鑶滅梾鍙樼殑褰㈡垚鏄庢樉鍑忓皯锛屼弗閲嶇▼搴︽槑鏄惧噺杞汇€備綔涓轰竴绉嶆姉鐐庝粙璐紝KYKZL-1 鍦 RAW 264.7 榧犲法鍣粏鑳炰腑浠ユ祿搴︿緷璧栨柟寮忔姂鍒朵簡 LPS 璇卞彂浜х敓涓€姘у寲姘€丳GE2 鍜 LTB4銆傛澶栵紝鍦 LPS-澶勭悊 RAW 264.7 缁嗚優涓紝KYKZL-1 娌荤枟鏄庢樉鍑忓皯浜嗗彲璇卞涓€姘у寲姘悎鎴愰叾銆丆OX-2 鍜 5-LOX鐨 mRNA 鍜岃泲鐧借川琛ㄨ揪銆傛渶鍚庯紝鍏朵骇鐗╂姂鍒朵簡缁嗚優澶栬皟鑺傛縺閰跺拰 p39 婵€閰剁殑纾烽吀鍖栵紝鎻愮ず璇ヨ嵂鍦ㄤ粙瀵兼姉鐐庢椿鎬т腑瀵逛笣瑁傚師娲诲寲铔嬬櫧婵€閰堕€氳矾鍏锋湁浣滅敤锛圶u, G.L. et al.Toxicol Appl Pharmacol 2013, 272(1): 221锛夈€
鏂板瀷鍐呯毊鑴傝偑閰舵姂鍒跺墏 XEN-445 鍗囬珮 HDL 鑳嗗浐閱囨按骞
Merck & Co. 鍜 Xenon Pharmaceuticals 涓ゅ鍏徃鐨勭瀛﹀浠彂鐜颁簡涓€绫绘柊鍨嬮偦姘ㄥ熀鑻敳閰稿彲浣滀负鍐呯毊鑴傝偑閰 (EDL) 鎶戝埗鍓傦紝骞跺湪灏忛紶涓〃鐜板嚭澧炲姞琛€娴 HDL 鑳嗗浐閱囨祿搴︾殑鑳藉姏銆備竴椤归珮閫氶噺绛涢€夎繍鍔ㄦ棬鍦ㄧ攧閫夊 EDL 鏈夋椿鎬х殑鍖栧悎鐗╋紝钘夋閴村畾鍑轰簡璧峰鐐癸紝瀵圭爺绌剁粨鏋 鈥 娲绘€у叧绯讳粯鍑虹殑鍔姏锛岄壌瀹氬嚭寮烘晥閫夋嫨鎬 EDL 鎶戝埗鍓傦紝XEN-445 渚挎槸涓€涓ず渚嬨€傚 EDL 杞煋浜鸿儙鑲 HEK-293 缁嗚優涓 XEN-445 鐨勬晥浠疯繘琛屾祴瀹氾紝寰楀埌鐨 IC50 涓 0.25 nM銆傚湪灏忛紶涓紝XEN-445 琛ㄧ幇鍑虹殑鍙f湇鐢熺墿鍒╃敤搴︿负 54%锛屾竻闄ょ巼杈冧綆銆備负浜嗚瘎浠峰 HDL 鑳嗗浐閱囩殑浣滅敤锛岃閲庣敓灏忛紶浠 30 mg/kg b.i.d. 浣跨敤浜 3 澶 XEN-445銆傜 4 澶╀笂鍗堥噰琛€鍒嗘瀽琛ㄦ槑琛€娴 XEN-445 骞冲潎姘村钩涓 9.9 mcM锛岃娴嗘€昏儐鍥洪唶鍜 HDL 鑳嗗浐閱囧垎鍒崌楂 18% 鍜 16%銆傝繕鍙戠幇浠 10 mg/kg b.i.d 娌荤枟 3 澶╃殑灏忛紶锛孒DL 鑳嗗浐閱囩害鍗囬珮 10%銆傜粰浜 3 澶 XEN-445骞舵湭鏀瑰彉 EDL 鏁查櫎灏忛紶鐨勮娴嗘€昏儐鍥洪唶鎴 HDL 鑳嗗浐閱囨祿搴︼紝璇存槑鍏朵綔鐢ㄦ簮鑷澏鏍囨姂鍒躲€傛渶鍚庯紝浠 30 mg/kg b.i.d. 娌荤枟 9 澶╋紝琛€娴 DHL 鑳嗗浐閱囧崌楂 30% 浠ヤ笂锛圫un, S. et al. Bioorg Med Chem 2013, 21(24): 7724锛夈€
SUGLAT 鐗囧湪鏃ユ湰鑾锋壒娌荤枟 2 鍨嬬硸灏跨梾
Astellas Pharma 鍏徃鐨 Suglat(R)锛堜紛鏍煎垪鍑€ L-鑴皑閰革紝ipragliflozin L-proline锛?5- 鍜 50-mg 鐗囧墏娌荤枟 2 鍨嬬硸灏跨梾鍦ㄦ棩鏈幏寰椾笂甯傝鍙瘉銆傝鍏徃浜 2013 骞 3 鏈堢敵鎶ユ鎵瑰噯銆備紛鏍煎垪鍑€ L-鑴皑閰稿睘浜庨€夋嫨鎬ч挔/閽?钁¤悇绯栬浆杩愯泲鐧借川绫 2 (SGLT2) 鎶戝埗鍓傦紝鏄笌 Kotobuki Pharmaceutical 鍏徃閫氳繃绉戠爺鍚堜綔鍙戠幇鍜屽紑鍙戠殑銆傝鑽€氳繃閫夋嫨鎬ф姂 SGLT2 鑰屾姂鍒惰憽钀勭硸鍐嶆憚鍙栵紝浠庤€岄檷浣庤绯栥€備紛鏍煎垪鍑€ L-鑴皑閰稿崟鑽不鐤楃殑涓€椤 III 鏈熷叧閿€ц瘯楠岋紝浠ュ強璇ヨ嵂涓庡叾浠栭檷绯栬嵂鑱旂敤鐨勫椤逛复搴婄爺绌讹紝鏀寔浜嗘湰鍝佸湪鏃ユ湰鐨勮幏鎵广€侫stellas 鍏徃灏嗗埗閫犲拰閿€鍞骇鍝侊紝骞朵笌 Kotobuki Pharmaceutical 鍜 MSD K.K. 涓ゅ鍏徃鍏卞悓鎺ㄥ箍锛堣 2013 骞 9 鏈 3 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級锛圓stellas Pharma 鏂伴椈绋匡級銆
灏忓垎瀛愰檷绯栬嵂鏂扮殑浣滅敤鏈哄埗瑙佹姤
Amgen 鍏徃鐮旂┒鑰呴壌瀹氬嚭灏忓垎瀛愯憽绯栨縺閰 (GK) 璋冭妭铔嬬櫧 (GCKR) 鎶戝埗鍓 AMG-1694 鍜 AMG-3969锛屼綔鐢ㄦ槸闄嶄綆钁¤悇绯栨按骞宠€屼笉浼氬鑷翠綆琛€绯栥€傛澶栵紝鏈枃浠嬬粛浜嗕汉浣 GCKR 涓師鍏堟湭閴村畾鐨勭粨鍚堣锛屼笉鍚屼簬涓庡北姊ㄩ唶-6-纾烽吀鐩愮粨鍚堝悗鎻愬崌 GK-GCKR 澶嶅悎浣撶ǔ瀹氭€х殑纾烽吀鏋滅硸缁撳悎浣嶇偣銆 GK 鍙皟鑺傝憽钀勭硸鍐呯ǔ鎬侊紝鍏惰嚜韬張鍙 GCKR 铔嬬櫧鐨勮皟鑺傦紝绌鸿吂鏃 GCKR 鍙縺娲 GK銆傞€嗚浆楂樿绯栫殑鍦ㄧ爺 GK 婵€娲诲墏鏄剧ず鍑哄鑷翠綆琛€绯栫殑涓嶈壇浣滅敤銆備絾閫氳繃鎶戝埗 GCKR 闂存帴澧炲姞 GK 娲绘€э紝鎴栧彲闃叉浣庤绯栫殑鍙戠敓銆傞壌瀹氬嚭鍩轰簬鍝屽棯鐨勫皬鍒嗗瓙寮烘晥 GCKR 鎶戝埗鍓 AMG-1694 鍜 AMG-3969銆侴CKR 浠ユ祿搴︿緷璧栨柟寮忔姂鍒朵簡 GK 娲绘€с€備絾鏈 GCKR 鏃讹紝AMG-1694 鎭㈠浜 GK 娲绘€э紝EC50 涓 0.02 mcM锛屼績杩涗簡 GK-GCKR 澶嶅悎鐗╃殑瑙g锛圛C50 = 0.007 mcM锛夛紝澧炲姞浜 GK 鐨勫埄鐢ㄥ害銆傚北姊ㄩ唶-6-纾烽吀鐩愬湪棣栦釜绯栧紓鏋勯叾锛圫IS锛夊煙涓庣硸纾烽吀缁撳悎浣嶇偣缁撳悎浠ュ鍔犵ǔ瀹氭€э紝鑰屾櫠浣撶粨鏋勮В鏋愬拰鎴煭 GCKR 鍒嗘瀽琛ㄦ槑锛孉MG-1694 涓庨涓 SIS 鍩熷拰 N-绔殑涔嬮棿鐨勪竴涓嫭鐗瑰尯鍩熺粨鍚堜互绋冲畾澶嶅悎浣撱€備笌杩欎竴鏂板瀷浣嶇偣缁撳悎鍚庣牬鍧忎簡澶嶅悎浣撶ǔ瀹氭€х殑鏈哄埗灏氫笉娓呮銆傚湪澶ч紶鍘熶唬鑲濈粏鑳炰腑锛孉MG-1694 寮曞彂浜 GK 浠庣粏鑳炴牳鏄撲綅鍒拌優娴嗭紙IC50 = 0.065 mcM锛夛紝澧炲姞浜 2-鑴辨哀-D-钁$硸纾烽吀锛圙K 娲诲寲鏍囪鐗╋級鐨勮搫绉紙EC50 = 0.053 mcM锛夈€傛甯稿ぇ榧犲拰 Zucker 绯栧翱鐥呰剛鑲ぇ榧犱腑锛孉MG-1694 浠ュ墏閲忎緷璧栨柟寮忎娇 GK 鏄撲綅姣旇憽钀勭硸鎴栨灉绯栨洿涓虹ǔ鍋ワ紝鑰屼笉浼氬奖鍝嶈娴嗚儼宀涚礌姘村钩銆傚湪琛€绯栨甯稿皬榧犱腑锛孉MG-1694 骞舵湭闄嶄綆琛€娴嗙硸钁¤悇绯栥€傜硸灏跨梾榧犳ā鍨嬩腑锛孉MG-3969 鏄庢樉闄嶄綆浜嗛珮琛€绯栵紙Lloyd, D.J. et al Nature 2013, 504(7480): 437锛夈€ 涓撳埄鏂囩尞涓粙缁嶄簡璇ュ寲鍚堢墿 (WO 2012027261)銆
TAXIS 鍏徃鎶ラ亾鍙f湇鏉€鑿屽墠鑽殑寮€鍙戝拰涓村簥鍓嶇壒鐐
Taxis Pharmaceuticals 鍏徃鐮旂┒浜哄憳浠嬬粛浜 PC-190723 鍓嶈嵂 TXY-436 鍜 TXY-541 鐨勬椿浣撳唴鑽姩瀛︽€ц川锛孭C-190723 鍙牬鍧忕粏鑿岀粏鑳炲垎瑁傝泲鐧 FtsZ锛岃憽钀勭悆鑿屾劅鏌撻紶妯″瀷涓〃鐜板嚭寮哄ぇ鎶楄弻鐤楁晥銆 鎰熸煋榧犳ā鍨嬬殑涓村簥鍓嶇爺绌惰〃鏄庤嫰鐢查叞鑳 PC-190723 鍏锋湁鎶楄弻鐤楁晥銆備絾 C-190723 鍙憾鎬у樊 (ClogP = 2.64)锛屼护鍏舵垚涓轰笉瀹滅敤浜庝汉浣撶殑鍊欓€夎嵂銆俆XY-436 鏄 PC-190723 鐨 N-鏇煎凹瑗跨⒈琛嶇敓鐗╋紝pH 涓 2.6 鏃跺叾鍙憾鎬 (ClogP = -0.51) 鏄瘝浣撳寲鍚堢墿鐨 100 鍊嶃€俻H 涓 7.4 鏃讹紝TXY-436 杞寲涓 PC-190723 鐨勫崐琛版湡鏄 18.2 +/鈥 1.6 鍒嗛挓銆俆XY-436 瀵瑰皬榧犺〃鐜板嚭鑹ソ鐨勫彛鏈嶇敓鐗╁埄鐢ㄥ害锛圥C-190723 鍓嶈嵂涓 33% 鍜 73%锛夛紝绋虫€佹椂鍒嗗竷瀹圭Н涓 5.77 L/kg銆俆XY-436 鍙婂悗缁 PC-190723 鐨勬秷闄ゅ崐琛版湡鍒嗗埆涓 0.26 鍜 0.96 灏忔椂銆俆XY-436 瀵硅憽钀勭悆鑿屽睘涓庢瘝鑽叿鏈夌浉浼肩殑鎶楄弻浣滅敤銆傚叏韬敳姘цタ鏋楁晱鎰熸垨鑰愯嵂鐨勯噾榛勮壊钁¤悇鐞冭弻鎰熸煋榧犳ā鍨嬩腑锛屽彛鏈 TXY-436 浣 67% 娌荤枟灏忛紶娑堥櫎浜嗕竴鑸細鑷存鐨勬劅鏌擄紝璇ヨ嵂瀵归潪娲茬豢鐚磋偩鑴忎笂鐨 Vero 缁嗚優浜︽棤姣掓€э紙Kaul, M. et al. Antimicrob Agents Chemother 2013, 57(12): 5860锛夈€ TXY-541 鏄 PC-190723 鐨 1-鐢插熀鍝屽暥-4-姘ㄧ敳閰板墠鑽紝鍦 10 mM 鏋告┘閰告恫 (pH 2.6) 涓殑鍙憾鎬ф槸姣嶈嵂鐨 143 鍊嶃€傜敓鐞嗘潯浠朵笅 (pH 7.4)锛孴XY-541 鍦ㄧ敓闀夸粙璐ㄤ腑杞寲涓 PC-190723 鐨勫崐琛版湡鏄 8.2 +/鈥 0.4 灏忔椂锛屼絾鍦ㄥ皬榧犺娓呬腑鐨勮浆鍖栭€熷害鏄 3.4 +/鈥 0.2 鍒嗛挓銆傚皬榧犺娓呬腑锛屾湰鍝佸钁¤悇鐞冭弻灞炰笌姣嶈嵂鍏锋湁鐩镐技鐨勬姉鑿屼綔鐢ㄣ€傚湪灏忛紶涓紝TXY-541-琛嶇敓 PC-190723 琛ㄧ幇鍑鸿壇濂界殑鍙f湇鐢熺墿鍒╃敤搴 (29.6%)锛屽湪 15 鍒嗛挓鍐呰揪鍒拌娴嗗嘲娴撳害锛岀ǔ鎬佹椂鍒嗗竷瀹圭Н涓 2.18 L/kg銆俆XY-541 浜х墿 PC-190723 鐨勬秷闄ゅ崐琛版湡涓 0.6 灏忔椂銆傚墠鑽钁¤悇鐞冭弻灞炰笌姣嶈嵂鍏锋湁鐩镐技鐨勬姉鑿屼綔鐢ㄣ€傚彛鏈 TXY-436 娌荤枟浣 100% 鍏ㄨ韩閲戣憽鑿屾劅鏌撳皬榧犳秷闄や簡涓€鑸細鑷存鐨勬劅鏌撱€傛澶栵紝璇ヨ嵂瀵归潪娲茬豢鐚翠笂鐨 Vero 缁嗚優鏃犳瘨鎬э紙Kaul, M. et al Biochem Pharmacol 2013, 86(12): 1699锛夈€
鍙戠幇鏂板瀷鍖栧悎鐗╂不鐤楀閲嶈€愯嵂缁撴牳鐥
Novartis 鍏徃鐨勭瀛﹀浠彂琛ㄤ簡涓ょ瘒鎶ラ亾锛屼粙缁嶄簡鍖栧悎鐗╁惒鍝?2-缇ч叞鑳猴紙NTD-219銆丯ITD-304 鍜 NITD-349锛夌殑璁捐銆佸悎鎴愬強涓村簥鍓嶇壒鐐癸紝鎷熺敤浜庡閲嶈€愯嵂缁撴牳鐥呯殑涓村簥娌荤枟銆傚鍒嗘灊鏉嗚弻鐨勮〃鍨嬬瓫鏌ラ壌鍒嚭鍚插摎-2-缇ч叞鑳烘槸涓€绉嶆綔鍦ㄦ姉缁撴牳鑽€傚鍏锋湁浜氭懇灏旀晥浠峰拰鍒嗘灊鏉嗚弻娲绘€х殑鍚插摎-2-缇ч叞鑳哄疄鏂戒簡缁撴瀯娲绘€у叧绯诲缓妯°€備慨楗板惒鍝氱幆鍜岀幆宸卞熀鍩哄洟浜х敓浜嗘椿浣撳鐮旂┒涓彈璇曠殑涓€绯诲垪鍖栧悎鐗┿€傝繖鏍锋鏌ュ浜轰綋缁嗚優鐨勭枟鏁堝拰缁嗚優姣掓€э紝鍦ㄦ椿浣撳唴璇曢獙涓骇鐢熶簡涓ょ鍏堝鍖栧悎鐗┿€侼ITD-304 鍜 NITD-349 琛ㄧ幇鍑鸿壇濂界殑姘存憾鎬у拰鑹ソ鐨勪唬璋㈢ǔ瀹氭€э紝MIC50 鍊煎垎鍒负 0.015 鍜 0.023 mcM銆傜敤鍙f湇鎴栭潤鑴変娇鐢 25 鍜 5 mg/kg 鐨勫皬榧犺瘎浠蜂簡鑽姩瀛︺€備袱绉嶅寲鍚堢墿琛ㄧ幇鍑鸿緝浣庣殑鍏ㄨ韩娓呴櫎鐜囷紝涓埌楂樻按骞冲垎甯冨绉紝鍗婅“鏈熻寖鍥翠粙浜 4.5鈥? 灏忔椂锛屽彛鏈嶇敓鐗╁埄鐢ㄥ害浠嬩簬 51% 鈥 53%銆傛€ユ€х粨鏍哥梾鐨勯紶妯″瀷涓紝鍙f湇 25 鍜 75 mg/kg NITD-304 鍒嗗埆浣胯偤鍏嬮殕褰㈡垚鍗曚綅鍑忓皯浜 2.6 鍜 4.8 涓鏁般€侼ITD-349 浣胯偤鍏嬮殕褰㈡垚鍗曚綅鍒嗗埆鍑忓皯 2.4 鍜 4.6 涓鏁帮紙Kondreddi, R.R. et al. J Med Chem 2013, 56(21): 8849锛夈€ NITD-304 鍜 NITD-349 瀵圭粨鏍稿垎鏋濇潌鑿 H37Rv 鐨勬晥浠锋槸寮傜儫鑲兼垨 PA-824鏄 10 鍊嶏紝鐤楁晥涓 TMC-207 鐩镐技銆備袱绉嶅寲鍚堢墿閮借〃鐜板嚭鏃堕棿鍜屾祿搴 鈥 渚濊禆鎬ф潃鑿屽姩鍔涘 (> 0.2 mcM)锛屽缂撴參鍜屽揩閫熺敓闀胯弻鏍湁鏁堬紝浣嗗涓嶅鍒剁殑瀹垮瓨鑿屾牚鏃犳晥銆侼ITD-219銆丯ITD-304 鍜 NITD-349锛?lt; 0.04 鈥 0.08 mcM锛夊缁撴牳鍒嗘灊鏉嗚弻澶氶噸鑰愯嵂鑿屾牚琛ㄧ幇鍑鸿嵂鏁堛€傞紶绫汇€佸暜榻垮姩鐗╁拰鐘被妯″瀷涓紝NITD-304 鍜 NITD-349 琛ㄧ幇鍑烘湁鍒╃殑鑽姩瀛︼紝娑堥櫎鍗婅“鏈熼暱锛屽彛鏈嶇敓鐗╁埄鐢ㄥ害楂橈紝琛€娴嗘毚闇查噺姘村钩瓒呰繃娲讳綋澶栬嵂鏁堟墍闇€姘村钩銆傞紶绫绘劅鏌撴ā鍨嬩腑锛孨ITD-304 鍜 NITD-349 娌荤枟 2 鍛ㄥ悗鐨勭枟鏁堜笌鍒╃骞崇浉杩戯紝浼樹簬涔欒兒涓侀唶銆傝繖浜涘寲鍚堢墿鏃犲壇浣滅敤锛屽彲鑹ソ鑰愬彈銆傜幇宸茶〃鏄庤繖浜涘寲鍚堢墿閫氳繃闃绘柇闇夎弻閰搁叝绮橀檮鍒扮粏鑳炲涓婏紝浠庤€屽彂鎸ョ粏鑿岀粏鑳炲鐢熺墿鍚堟垚鎶戝埗鍓傜殑浣滅敤锛圧ao, S.P.S. et al. Sci Transl Med 2013, 5(214): 1锛夈€
AIC-649 鐢ㄤ簬鎱㈡€х梾姣掓€ф劅鏌撴不鐤楁柊绛栫暐鐨勪复搴婂墠寮€鍙
鍦ㄥ濞佸し鐨 HEP DART浼氳涓婏紝AiCuris 鍏徃鎶ュ憡浜嗕竴绉嶅埡婵€瀵规寔缁€х梾姣掓劅鏌擄紙鍖呮嫭涔欏瀷鑲濈値鐥呮瘨锛孒BV锛夊仛鍑哄厤鐤簲绛旂殑鏂版柟娉曘€ 杩欎竴绛栫暐涓娇鐢ㄤ簡鐏椿鍓棙鐥呮瘨棰楃矑鍒跺墏 AIC-649 鍒烘縺鍏嶇柅搴旂瓟銆傜幇鍦ㄥ凡鐭ュ壇鐥樼梾姣掑叿鏈夐潪鐗瑰紓鎬с€佸箍璋卞厤鐤埡婵€娲绘€с€傚皬榧犵粡闈欒剦缁欎簣鍗曞墏閲 AIC-649 鍒烘縺浜嗙粏鑳炲洜瀛愮殑閲婃斁锛屽寘鎷共鎵扮礌纬 鍜 伪銆乀NF-伪銆佸崟鏍哥粏鑳炶秼鍖栬泲鐧 1 (MCP-1) 鍙婄櫧浠嬬礌-6 (IL-6)銆傛澶栵紝鍦ㄨ浆鍩哄洜灏忛紶妯″瀷涓紝AIC-649 闄嶄綆 HBV 鐥呮瘨杞介噺鐨勪綔鐢ㄤ笌娉拌绂忛煢鐩镐豢銆備娇鐢ㄨ繖涓€绛栫暐鐨勬洿澶氳瘉鎹潵鑷浛浠 HBV 鐨勬棻鐛倽鐐庣梾姣 (WHV)銆傛劅鏌撴棻鐛娇鐢 AIC-649 鍚庯紝WHV 琛ㄩ潰鎶楀師姘村钩鏄庢樉闄嶄綆銆傛湰鐮旂┒涓烘參鎬ф劅鏌撹儗鏅笅浣跨敤杩欎竴璇曢獙鎬ф不鐤楃殑鍏嶇柅鍒烘縺娲绘€ф彁渚涗簡姒傚康楠岃瘉銆傝繖涓€娌荤枟鏈夊笇鏈涗笌鎶楃梾姣掕嵂鑱斿悎浣跨敤鏀瑰杽瀹夸富鍏嶇柅搴旂瓟锛岀洰鍓嶆鍦ㄨ繘鍏 I 鏈熶复搴婅瘯楠屻€傛嵁鎺ㄦ祴锛孉IC-649 浣滅敤浜庢姉鐥呮瘨淇″彿浼犻€掗€氳矾鐨勬瀬鏃╅樁娈碉紝鍙兘鏄€氳繃鍒烘縺鎶楀師鍛堥€掔粏鑳炴縺娲 T 缁嗚優銆傛澶栬繕鎻愮ず杩欎竴閫斿緞閽堝鍏朵粬鎱㈡€х梾姣掓€ф劅鏌撳彲鑳戒篃鏈夊箍娉涗綔鐢紝濡傚崟绾柋鐤圭梾姣 (HSV) 鎴 HIV銆傚湪涓€涓尶鐚村厤鐤己闄风梾姣 (SIV) 妯″瀷涓紝鎶楅€嗚浆褰曠梾姣掔枟娉曡仈鍚 AIC-649 浣垮緱 CD4 缁嗚優澧炲鍜岀敓瀛樻湡寤堕暱锛圥aulsen, D. et al. HEP DART (Dec 8-12, Kohala Coast, Hawaii) 2013, Abst 111锛夈€
鍙戠幇娌荤枟鐤熺柧鐨勬柊铔嬬櫧闈舵爣鍜屾柊鍨嬪寲鍚堢墿
鍥界珛鍗敓鐮旂┒闄 (NIH) 璧勫姪鐨勪竴涓爺绌跺洟闃熷彂鐜颁簡纾疯剛閰拌倢閱 4-OH 婵€閰 (PI4K) III 鍨 尾 (PI4KIIIbeta)锛岃繖绉嶈泲鐧借川鏄枱鍘熻櫕灞炵敓鍛藉懆鏈熸墍鏈夐樁娈甸兘閮藉繀椤荤殑銆傛澶栵紝浠栦滑鎶ラ亾鍙戠幇浜嗕竴绫绘柊鐨勫寲鍚堢墿鍜攽骞跺悺鍡紙imidazopyrazine锛夊寲鍚堢墿锛堝寘鎷琄AI-407銆並DU-691 鍜 KAI-715锛夊強涓€绉嶅柟鍣佸晧 BQR-695锛岄拡瀵瑰苟鍙姂鍒惰繖绉嶈泲鐧借川锛屽皢鎴愪负娌荤枟鐤熺柧鐨勪竴鎵规柊鑽€ 鐜版湁鐨勬姉鐤熻嵂閽堝鐨勬槸鎼哄甫鐤熺柧鐨勫瘎鐢熻櫕锛屽彧鑳介拡瀵瑰彂鑲蹭腑鐨勬煇涓樁娈点€傞拡瀵瑰瘎鐢熻櫕鐢熷懡鍛ㄦ湡鎵€鏈夐樁娈电殑鑽墿鏄汉浠ⅵ瀵愪互姹傜殑銆備竴绉嶅熀浜庣粏鑳炵殑鎭舵€х枱鍘熻櫕绛涙煡鎻ず浜嗕竴绫绘柊鐨勫挭鍞戝苟鍚″棯鎶楃枱鑽紝瀵瑰嚑绉嶈€愯嵂瀵勭敓铏搧绯绘湁鏁堛€傚熀浜庣粏鑳炵殑妫€鏌ヤ腑锛孠AI-407銆並DU-691 鍜 KAI-715 鍧囧鍟娇鍔ㄧ墿瀵勭敓铏害姘忕枱鍘熻櫕鍦ㄨ倽鑴忛樁娈电殑鍙戣偛鏈夋晥銆侹DU-691 鍦ㄥ皬榧犳椿浣撳唴闃叉浜嗕集姘忕枱鍘熻櫕鎰熸煋鎵€鑷存浜°€傛澶栵紝KDU-691 鍒氬湪鑲濊剰鍙戠敓闃舵涔嬪悗灏辨秷鐏簡瀵勭敓铏€備綆鍓傞噺鏃惰繕瀵圭尨鐤熷師铏畾灞呰倽鑴忎紤鐪犲瓙鏈夋晥锛圛C50 = 196 nM锛夛紝瀵逛汉闂存棩鐤熷師铏 (IC50 = 69 nM) 鍜屾伓鎬х枱鍘熻櫕 (IC50 = 118 nM) 琛€娑叉湡浼戠湢瀛愪篃鏈夋晥銆侹DU-691 鑳戒互鍓傞噺渚濊禆鏂瑰紡锛屽己鍔涢檷浣庨厤瀛愭瘝缁嗚優娲诲姏 (IC50 = 220 nM)锛岄樆鏂叾浼犳挱缁欒殜瀛 (IC50 = 316 nM)銆傝瀵熷埌 KAI-407 娌荤枟鎶戝埗浜嗙孩缁嗚優鍐呭懆鏈熷唴鏋佹櫄鏈熺殑琛€娑查樁娈佃優璐ㄥ垎瑁傦紝鍙戠幇鏄敱璐ㄨ啘鍐呯Щ鎵€鑷淬€傚 KAI-407 鑰愯嵂鎭舵€х枱鍘熻櫕鐨勯仐浼犵瓫鏌ラ壌鍒嚭瀵勭敓铏剛鑲縺閰秔fpi4k 绐佸彉锛屾彁绀虹壒鏄挭鍞戝苟鍚″棯绫诲箍娉涚壒寮傛€х殑娼滃湪闈舵爣銆侭QR-695 灞炰簬鍠瑰檨鍟夛紝閽堝鐨勪篃鏄 PI4KIIIbeta锛屽 KAI-407 鑰愯嵂鎭舵€х枱鍘熻櫕鍚屾牱鏃犳晥銆傚鑰愯嵂瀵勭敓铏殑閬椾紶鏀归€犺鍙戜簡瀵 KAI-407 鐨勬晱鎰熸€э紝璇佸疄 PI4KIIIbeta 鏄竴涓柊鍨嬫姉鐤熻嵂鐗╅澏鏍 (McNamara, C.W. et al. Nature 2013, 504(7479): 248)銆
TORII 鍏徃鑸屼笅鍏嶇柅娌荤枟鑽不鐤楁棩鏈鏌忚姳绮夊湪鏃ユ湰鑾锋壒
Torii Pharmaceutical 鍏徃鐨 Cedartolen(R) 鑸屼笅婊村墏鈥撴棩鏈鏌忚姳绮夊湪鏃ユ湰鑾峰緱鎵瑰噯锛岃繖绉嶈垖涓嬪厤鐤不鐤楄嵂娌荤殑閫傚簲鐥囨槸鏃ユ湰棣欐煆鑺辩矇鐑€傛敮鎸佸叾鑾锋壒鐨勬槸鏃ユ湰棣欐煆鑺辩矇鐑偅鑰呯殑涓€椤 III 鏈熸棩鏈爺绌讹紝璇ョ爺绌惰揪鍒颁簡鍏朵富瑕佺枟鏁堢粓鐐癸紝琛ㄦ槑 Cedartolen 娌荤枟缁撴潫鏃跺鍑忚交鎬讳綋榧昏厰鐥囩姸鍙婇檷浣庣敤鑽瘎鍒嗘槑鏄句紭浜庡畨鎱板墏锛屽叿鏈夌粺璁″鎰忎箟锛堣 2012 骞 9 鏈 17 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆傛鑽兘鍦ㄥ浣跨敤锛岃璁$洰鐨勬槸鍙栦唬鐨笅娉ㄥ皠锛圱orii Pharmaceutical 鏂伴椈绋匡級銆侟/p>
浣滆€咃細涓嶈銆€鏉ユ簮锛氭堡濮嗘.璺€廃/div>